Skip to main content
. 2015 Oct 7;2015(10):CD010081. doi: 10.1002/14651858.CD010081.pub2

NCT01838499.

Trial name or title A Phase IIa Randomized, Double‐Blind, Placebo‐controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Methods This is a phase 2 parallel RCT
Participants Participants must be aged 18 to 65 years with moderate to severe HS
Interventions
  • MEDI8968 subcutaneous injection at baseline, week 4, and week 8/saline subcutaneous injection at baseline, week 4, and week 8

Outcomes
  1. Proportion of participants achieving a clinically relevant response in the Physician Global Assessment (PGA), with score 0, 1, or 2 at 12 weeks

Starting date May 2013
Contact information Dr Robert AK Lee
Notes AstraZeneca sponsors the trial